Original paper
P1.04-50 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Abstract
Pembrolizumab has demonstrated its usefulness as a primary treatment for metastatic non-small cell lung cancer (NSCLC) in Keynote-024 and Keynote-042. However, there is little information on the usefulness of pembrolizumab in clinical practice. The purpose of this study is to examine whether the efficacy reported in Keynote-024 and Keynote-042 is reproduced in real world setting. This study is retrospective multicenter trial. From Feb 2017 to...
Paper Details
Title
P1.04-50 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Published Date
Oct 1, 2019
Journal
Volume
14
Issue
10
Pages
S460 - S460
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History